Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

RESHAPE LIFESCIENCES INC.

(RSLS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Obalon Therapeutics : Amendments to articles of incorporation/bylaws/change in fiscal year (Form 8-K)

06/15/2021 | 05:14pm EDT
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On June 15, 2021, the Company filed (a) the Certificate of Third Amendment with the Secretary of State of the State of Delaware to effect the Reverse Stock Split after the close of trading on June 15, 2021, (b) the Series C Certificate of Designation, and (c) a Certificate of Fourth Amendment (the 'Certificate of Fourth Amendment') with the Secretary of State of the State of Delaware to amend the Company's Restated Certificate of Incorporation, as amended, to change its corporate name to ReShape Lifesciences Inc. effective after the close of trading on June 15, 2021. The information set forth in Item 3.03 of this Current Report is incorporated by reference herein. The foregoing descriptions of the Certificate of Third Amendment and Certificate of Fourth Amendment are qualified in their entirety by reference to the Certificate of Third Amendment and Certificate of Fourth Amendment, which are filed as Exhibit 3.1 and Exhibit 3.2, respectively, to this Current Report and are incorporated herein by reference.

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
Number
Description
2.1 Agreement and Plan of Merger, dated January 19, 2021, by and among Obalon Therapeutics, Inc., Optimus Merger Sub, Inc., and ReShape Lifesciences Inc. (incorporated by reference to Exhibit 2.1 to Obalon Therapeutics, Inc.'s Current Report on Form 8-K, filed with the SEC on January 20, 2021).*
3.1 Third Amendment to the Amended and Restated Certificate of Incorporation of the Company.
3.2 Fourth Amendment to the Amended and Restated Certificate of Incorporation of the Company
3.3 Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock
104 Cover Page Interactive Data File (embedded with the inline XBRL document)

* Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company hereby undertakes to furnish supplementally copies of any of the omitted schedules upon request by the SEC; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedule so furnished.

Disclaimer

Obalon Therapeutics Inc. published this content on 15 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 June 2021 21:13:01 UTC.


ę Publicnow 2021
All news about RESHAPE LIFESCIENCES INC.
09/13RESHAPE LIFESCIENCES : trade; to Host Exhibit at Bariatric Summit
AQ
09/09ReShape Lifesciences™ to Present at Oppenheimer Fall Healthcare Life Sciences and..
GL
08/31RESHAPE LIFESCIENCES : trade; Appoints Al Diaz as Vice President of Operations and Researc..
AQ
08/16RESHAPE LIFESCIENCES : Reports Second Quarter 2021 Financial Results and Provides Business..
PU
08/16Reshape Lifesciences Inc. Reports Earnings Results for the Second Quarter Ended June 30..
CI
08/16RESHAPE LIFESCIENCES : Reports Second Quarter 2021 Financial Results and Provides Business..
PU
08/16RESHAPE LIFESCIENCES : Earnings Flash (RSLS) RESHAPE LIFESCIENCES Reports Q2 Revenue $3.5M
MT
08/03RESHAPE LIFESCIENCES : TM) CEO Bart Bandy Featured on the Big Biz Show
PU
07/29RESHAPE LIFESCIENCES : to Report Second Quarter 2021 Financial and Operational Results on ..
PU
07/07RESHAPE LIFESCIENCES : Moves Lap-Band Manufacturing to United States
PU
More news
Analyst Recommendations on RESHAPE LIFESCIENCES INC.
More recommendations
Financials (USD)
Sales 2021 15,3 M - -
Net income 2021 -16,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,04x
Yield 2021 -
Capitalization 19,4 M 19,4 M -
Capi. / Sales 2021 1,27x
Capi. / Sales 2022 0,95x
Nbr of Employees 37
Free-Float 99,1%
Chart RESHAPE LIFESCIENCES INC.
Duration : Period :
ReShape Lifesciences Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESHAPE LIFESCIENCES INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 2,85 $
Average target price 10,25 $
Spread / Average Target 260%
EPS Revisions
Managers and Directors
Barton P. Bandy President, Chief Executive Officer & Director
Thomas Stankovich Chief Financial Officer, Secretary & Senior VP
Dan W. Gladney Chairman
Rajesh Nihalani Chief Technology Officer & Business Development
Dov Gal Vice President-Regulatory & Clinical Affairs
Sector and Competitors
1st jan.Capi. (M$)
RESHAPE LIFESCIENCES INC.-36.67%19
THERMO FISHER SCIENTIFIC26.71%234 887
DANAHER CORPORATION45.90%231 803
INTUITIVE SURGICAL, INC.23.95%120 661
SIEMENS HEALTHINEERS AG43.02%78 963
EDWARDS LIFESCIENCES CORPORATION29.33%73 864